M Bua

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Dragana Milojković, Emma Nicholson, Jane F. Apperley et al. · Haematologica · 2009 · 122 citations · Full text

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse

David Marin, Jaspal Kaeda, Richard Szydlo et al. · Leukemia · 2005 · 104 citations · Full text

Chronic Phase, Chromatin, Hematological Malignancy +11

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

David Marín, Sarah Marktel, M Bua et al. · Leukemia · 2003 · 71 citations

Chronic Phase, Prognostic Factors, Hematological Malignancy +9

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

David Marín, Ian H Gabriel, Sohail Ahmad et al. · Leukemia · 2011 · 52 citations

Hematological Malignancy, Oncology, Medicine +9

Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy

Maria Paola Simula, Sarah Marktel, Claudio Fozza et al. · Leukemia · 2007 · 51 citations · Full text

Hematological Malignancy, Chronic Myeloid Leukemia, Transplantation +11